Flinton Capital Management LLC Cuts Stake in Bristol-Myers Squibb Co (NYSE:BMY)

Flinton Capital Management LLC cut its position in Bristol-Myers Squibb Co (NYSE:BMY) by 12.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 26,824 shares of the biopharmaceutical company’s stock after selling 3,752 shares during the period. Flinton Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $1,394,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently bought and sold shares of BMY. Capital Investment Counsel Inc lifted its holdings in Bristol-Myers Squibb by 3.4% during the 4th quarter. Capital Investment Counsel Inc now owns 6,156 shares of the biopharmaceutical company’s stock valued at $320,000 after buying an additional 200 shares in the last quarter. Seizert Capital Partners LLC increased its position in Bristol-Myers Squibb by 3.8% during the 4th quarter. Seizert Capital Partners LLC now owns 6,069 shares of the biopharmaceutical company’s stock valued at $315,000 after purchasing an additional 224 shares during the period. Private Wealth Advisors Inc. increased its position in Bristol-Myers Squibb by 5.0% during the 4th quarter. Private Wealth Advisors Inc. now owns 4,873 shares of the biopharmaceutical company’s stock valued at $253,000 after purchasing an additional 232 shares during the period. Banced Corp increased its position in Bristol-Myers Squibb by 2.3% during the 4th quarter. Banced Corp now owns 10,745 shares of the biopharmaceutical company’s stock valued at $559,000 after purchasing an additional 242 shares during the period. Finally, Carroll Financial Associates Inc. increased its position in Bristol-Myers Squibb by 1.5% during the 4th quarter. Carroll Financial Associates Inc. now owns 17,024 shares of the biopharmaceutical company’s stock valued at $824,000 after purchasing an additional 248 shares during the period. 74.28% of the stock is owned by institutional investors.

A number of brokerages have recently issued reports on BMY. BMO Capital Markets reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Bristol-Myers Squibb in a research report on Thursday, January 3rd. Zacks Investment Research raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $60.00 price objective on the stock in a research report on Tuesday, March 5th. Societe Generale raised shares of Bristol-Myers Squibb from a “sell” rating to a “buy” rating in a research report on Tuesday, January 15th. Credit Suisse Group reaffirmed a “hold” rating and issued a $59.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, February 15th. Finally, Bank of America set a $53.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Friday, January 25th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $59.14.

Shares of BMY traded down $0.28 during trading hours on Friday, hitting $45.52. The stock had a trading volume of 23,633,791 shares, compared to its average volume of 19,861,882. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.61 and a quick ratio of 1.50. Bristol-Myers Squibb Co has a fifty-two week low of $44.30 and a fifty-two week high of $63.69. The stock has a market cap of $74.38 billion, a P/E ratio of 11.44, a P/E/G ratio of 2.34 and a beta of 0.79.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.09. The firm had revenue of $5.97 billion during the quarter, compared to analysts’ expectations of $5.95 billion. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 48.99%. The business’s revenue was up 9.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.68 EPS. Equities analysts expect that Bristol-Myers Squibb Co will post 4.16 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be issued a $0.41 dividend. This represents a $1.64 annualized dividend and a yield of 3.60%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is presently 41.21%.

ILLEGAL ACTIVITY WARNING: “Flinton Capital Management LLC Cuts Stake in Bristol-Myers Squibb Co (NYSE:BMY)” was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/flinton-capital-management-llc-has-1-39-million-holdings-in-bristol-myers-squibb-co-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: How to Use a Moving Average for Trading 

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.